These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37062189)

  • 1. Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Funck KL; Petersen L; Bek T; Poulsen PL; Laugesen E
    J Diabetes Complications; 2023 May; 37(5):108472. PubMed ID: 37062189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Funck KL; Poulsen PL; Laugesen E
    Diabetologia; 2023 May; 66(5):813-825. PubMed ID: 36746803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
    Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Birn H; Funck KL; Poulsen PL; Laugesen E
    J Diabetes Complications; 2024 Feb; 38(2):108673. PubMed ID: 38219335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
    Vernstrøm L; Gullaksen S; Sørensen SS; Funck KL; Laugesen E; Poulsen PL
    Diabetes Obes Metab; 2024 May; 26(5):1624-1635. PubMed ID: 38240066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.
    Reppo I; Jakobson M; Volke V
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.